Published in Br J Clin Pharmacol on August 01, 2013
Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma | NCT01103635
Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma | NCT00790010
Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer | NCT01644968
Immunotherapy With Racotumomab in Advanced Lung Cancer | NCT01460472
Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer | NCT01074021
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood (2016) 1.04
Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking. Front Chem (2014) 0.89
Synthetic biology in cell-based cancer immunotherapy. Trends Biotechnol (2015) 0.84
Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. Immunotherapy (2015) 0.81
Countering immunotoxin immunogenicity. Br J Cancer (2016) 0.78
Induction of HLA-A*33-restricted cytotoxic lymphocytes against renal cell carcinoma targeting galectin 9 and PINCH. Biomed Rep (2014) 0.77
Present and future perspectives on immunotherapy for advanced renal cell carcinoma: Going to the core or beating around the bush? J Kidney Cancer VHL (2015) 0.75
From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis. World J Clin Oncol (2017) 0.75
Biological therapies: a long way on from Jenner. Br J Clin Pharmacol (2013) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med (2004) 30.26
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med (2009) 22.23
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med (2007) 20.19
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med (2002) 19.60
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (1995) 16.19
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet (2007) 15.92
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity (1995) 14.90
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol (2009) 14.15
Tolerogenic dendritic cells. Annu Rev Immunol (2001) 13.77
T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature (1998) 12.70
Cancer immunotherapy comes of age. Nature (2011) 12.35
A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature (1998) 12.07
Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med (2008) 11.86
Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature (1998) 11.08
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol (2007) 11.04
Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer (2005) 10.06
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol (2010) 9.29
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol (2008) 8.79
A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med (2011) 8.63
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol (1998) 8.40
Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol (2008) 8.17
A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science (1986) 8.07
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (2011) 7.95
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol (2005) 7.80
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A (2007) 7.49
TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol (2005) 7.44
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol (2012) 6.78
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A (2003) 5.49
Mechanisms of immune evasion by tumors. Adv Immunol (2006) 5.34
Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol (2012) 5.23
Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer (2012) 5.15
Making antibodies by phage display technology. Annu Rev Immunol (1994) 5.04
Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol (2003) 5.01
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol (2010) 4.79
BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol (2003) 4.56
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol (2012) 4.44
Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature (1986) 4.19
Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood (2008) 4.10
Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist (2007) 4.01
CD27 is required for generation and long-term maintenance of T cell immunity. Nat Immunol (2000) 3.84
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res (2011) 3.81
Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2009) 3.79
B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol (2004) 3.49
CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol (2004) 3.36
Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A (1984) 3.32
Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med (1999) 3.29
Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. J Clin Invest (2011) 3.28
4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med (2004) 3.01
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol (2007) 2.92
Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol (2003) 2.87
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med (2011) 2.86
CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med (1999) 2.77
Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol (2010) 2.67
Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science (2011) 2.63
CD27 promotes survival of activated T cells and complements CD28 in generation and establishment of the effector T cell pool. J Exp Med (2003) 2.62
CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med (1999) 2.61
Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res (1985) 2.60
Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res (2011) 2.59
Properties of mouse and human IgG receptors and their contribution to disease models. Blood (2012) 2.53
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol (2007) 2.50
PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res (2012) 2.43
Inducible T cell antigen 4-1BB. Analysis of expression and function. J Immunol (1993) 2.40
Production of functional chimaeric mouse/human antibody. Nature (1985) 2.35
Management and preparedness for infusion and hypersensitivity reactions. Oncologist (2007) 2.29
In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses. J Exp Med (2005) 2.28
LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J Immunol (2000) 2.27
CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res (2011) 2.26
A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res (2007) 2.24
A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A (1989) 2.23
CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med (2009) 2.23
Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat Med (2002) 2.23
Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity (1995) 2.17
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol (2012) 2.14
NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol (1998) 2.11
Ox40-ligand has a critical costimulatory role in dendritic cell:T cell interactions. Immunity (1999) 2.02
Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood (1999) 1.90
PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. J Exp Med (2011) 1.80
Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol (2011) 1.79
Role of 4-1BB in immune responses. Semin Immunol (1998) 1.77
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med (2011) 1.77
Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol (2000) 1.74
Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One (2011) 1.73
BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest (2009) 1.71
Cutting edge: Expression of functional CD137 receptor by dendritic cells. J Immunol (2002) 1.70
Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J Immunol (1999) 1.69
Human immune response to multiple injections of murine monoclonal IgG. J Immunol (1985) 1.68
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med (2013) 6.70
Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer (2007) 5.65
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med (2015) 5.44
Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging (2010) 2.48
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood (2008) 2.17
Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling. J Immunol Methods (2008) 2.03
Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. Blood (2002) 2.01
The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol (2003) 1.82
In vivo preclinical photoacoustic imaging of tumor vasculature development and therapy. J Biomed Opt (2012) 1.59
Spontaneous clinical regression in chronic lymphocytic leukaemia. Br J Haematol (2002) 1.45
C/EBPalpha deficiency results in hyperproliferation of hematopoietic progenitor cells and disrupts macrophage development in vitro and in vivo. Blood (2004) 1.41
Written emotional disclosure buffers the effects of social constraints on distress among cancer patients. Health Psychol (2004) 1.33
Effective in-service training design and delivery: evidence from an integrative literature review. Hum Resour Health (2013) 1.23
Left frontal cortical activation and spreading of alternatives: tests of the action-based model of dissonance. J Pers Soc Psychol (2008) 1.19
Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. J Clin Oncol (2013) 1.18
Up-regulation of the embryonic self-renewal network through reversible polyploidy in irradiated p53-mutant tumour cells. Exp Cell Res (2010) 1.14
Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins. Proc Natl Acad Sci U S A (2010) 1.14
Primary mediastinal large B-cell lymphoma. Crit Rev Oncol Hematol (2008) 1.12
Social barriers to emotional expression and their relations to distress in male and female cancer patients. Br J Health Psychol (2003) 1.11
Response to Nelissen et al., Helping mothers survive bleeding after birth: an evaluation of simulation-based training in a low-resource setting. Acta Obstet Gynecol Scand (2014) 1.08
Leadership in surgery for public sector hospitals in Jamaica: strategies for the operating room. Perm J (2013) 1.04
Homocysteine and its derivatives as possible modulators of neuronal and non-neuronal cell glutamate receptors in Alzheimer's disease. J Alzheimers Dis (2007) 1.04
The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study. Br J Haematol (2006) 1.03
Tumor suppressor function of Syk in human MCF10A in vitro and normal mouse mammary epithelium in vivo. PLoS One (2009) 1.03
A single locus is responsible for salinity tolerance in a Chinese landrace barley (Hordeum vulgare L.). PLoS One (2012) 1.02
Emerging evidence for a similar role of glutamate receptors in the nervous and immune systems. J Neurochem (2005) 0.99
Prediction of single-nucleotide substitutions that result in exon skipping: identification of a splicing silencer in BRCA1 exon 6. Hum Mutat (2011) 0.99
Mechanism of action of rituximab. Anticancer Drugs (2002) 0.98
DNA vaccines to attack cancer. Proc Natl Acad Sci U S A (2004) 0.98
Intimate cell conjugate formation and exchange of membrane lipids precede apoptosis induction in target cells during antibody-dependent, granulocyte-mediated cytotoxicity. J Immunol (2007) 0.97
Fabrication and characterization of a multilayered optical tissue model with embedded scattering microspheres in polymeric materials. Biomed Opt Express (2012) 0.95
In vivo photoacoustic imaging of mouse embryos. J Biomed Opt (2012) 0.94
Breast cancer is a promising target for vaccination using cancer-testis antigens known to elicit immune responses. Breast Cancer Res (2007) 0.92
Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT. Blood (2013) 0.90
Sharing best practices through online communities of practice: a case study. Hum Resour Health (2010) 0.90
Multicenter retrospective analysis of the solid-screw ITI implant for posterior single-tooth replacements. Int J Oral Maxillofac Implants (2002) 0.89
Measuring low back injury risk factors in challenging work environments: an evaluation of cost and feasibility. Am J Ind Med (2007) 0.89
Nuclear envelope-limited chromatin sheets are part of mitotic death. Histochem Cell Biol (2002) 0.87
Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35/98). Br J Haematol (2014) 0.86
Microscopic intratumoral dosimetry of radiolabeled antibodies is a critical determinant of successful radioimmunotherapy in B-cell lymphoma. Cancer Res (2007) 0.86
Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas. Immunotherapy (2014) 0.85
Does the vagus nerve inform the brain about preclinical tumours and modulate them? Lancet Oncol (2005) 0.84
Rodent lymphocytes express functionally active glutamate receptors. Biochem Biophys Res Commun (2004) 0.84
The excitotoxic effect of NMDA on human lymphocyte immune function. Neurochem Int (2007) 0.84
Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia. Br J Haematol (2010) 0.83
SKR-1, a homolog of Skp1 and a member of the SCF(SEL-10) complex, regulates sex-determination and LIN-12/Notch signaling in C. elegans. Dev Biol (2008) 0.83
Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. Transplantation (2004) 0.82
Enumeration and phenotypic assessment of human plasmacytoid and myeloid dendritic cells in whole blood. Cytometry A (2010) 0.82
Competency-based education: the essential basis of pre-service education for the professional midwifery workforce. Midwifery (2013) 0.82
Opposing effects of age and calorie restriction on molecular determinants of myocardial ischemic tolerance. Rejuvenation Res (2012) 0.81
General utilities of multislice tomography in the cardiac field. Herz (2003) 0.81
The relationship between threat appraisal and social constraints in cancer survivors and their spouses. J Behav Med (2006) 0.80
University students' notebook computer use. Appl Ergon (2008) 0.80
Time-lapse imaging of primary preneoplastic mammary epithelial cells derived from genetically engineered mouse models of breast cancer. J Vis Exp (2013) 0.80
Using observation and self-report to predict mean, 90th percentile, and cumulative low back muscle activity in heavy industry workers. Ann Occup Hyg (2010) 0.79
Electronic colon-cleansing for CT colonography: diagnostic performance. Abdom Imaging (2009) 0.78
Breast cancer cell movement: imaging invadopodia by TIRF and IRM microscopy. Methods Mol Biol (2009) 0.77
New developments and challenges in the use of the UK DNA Database: addressing the issue of contaminated consumables. Forensic Sci Int (2004) 0.77
Erythrocyte and plasma protein modification in alcoholism: a possible role of acetaldehyde. Biochim Biophys Acta (2006) 0.77
Optimising sampling strategies: components of low-back EMG variability in five heavy industries. Occup Environ Med (2010) 0.77
Eradication of common pathogens at days 2, 3 and 4 of moxifloxacin therapy in patients with acute bacterial sinusitis. BMC Ear Nose Throat Disord (2006) 0.77
The Use of Anti-CD40 mAb in Cancer. Curr Top Microbiol Immunol (2015) 0.76
Steviamine, a new class of indolizidine alkaloid [(1R,2S,3R,5R,8aR)-3-hydroxy-meth-yl-5-methyl-octa-hydro-indolizine-1,2-diol hydro-bromide]. Acta Crystallogr Sect E Struct Rep Online (2009) 0.75
A role for neutrophils in rituximab therapy? Leuk Res (2010) 0.75
Left colon and liver hemangiomas. Can J Surg (2009) 0.75
Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. N Engl J Med (2016) 0.75
885: PHARMACOKINETIC EFFECT OF OBESITY ON FENTANYL CONTINUOUS INFUSIONS IN CHILDREN. Crit Care Med (2016) 0.75
Liability insurance in midwifery education: faculty and student needs versus academic realities. J Prof Nurs (2007) 0.75
Predicting erythroid response to recombinant erythropoietin plus granulocyte colony-stimulating factor therapy following a single subcutaneous bolus in patients with myelodysplasia. Haematologica (2006) 0.75
Neuroblastoma in a 17-week fetus: a stimulus for investigation of tumors in a series of 2786 stillbirth and late miscarriages. Am J Med Genet A (2014) 0.75
The 1999-2000 task analysis of American nurse-midwifery/midwifery practice. J Midwifery Womens Health (2002) 0.75
Straight versus modiolar hugging electrodes: does one perform better than the other? Otol Neurotol (2015) 0.75
Design and evaluation of a curved computer keyboard. Ergonomics (2009) 0.75
Recognition of facial expressions of emotion in adults with Down syndrome. Phys Occup Ther Pediatr (2012) 0.75
Modification of the butenyl-spinosyns utilizing cross-metathesis. Bioorg Med Chem (2009) 0.75
Treating cocaine body packers: the unspoken personal risks. J Forensic Leg Med (2008) 0.75
Straight vs. modiolar hugging electrodes--does one perform better than the other? Cochlear Implants Int (2015) 0.75
A hyperplastic cause of hyperemesis. Gut (2013) 0.75
The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol (2003) 0.75
Occupational hazard: treating cocaine body packers in Caribbean countries. Int J Drug Policy (2008) 0.75
Corrigendum: Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. Nat Genet (2016) 0.75